-transparent.png){kind=logo}
Platelet serotonin (5-hydroxytryptamine, 5-HT) uptake sites were studied in a control group (n = 30) and an Alzheimer group (n = 40) using [3H]paroxetine as radioligand. The maximum number of binding sites (Bmax) for control (1250 +/- 60 fmol/mg protein) was not different from the Alzheimer group (1280 +/- 40 fmol/mg protein). There were no differences in apparent binding affinity (Kd): 0.046 (0.024-0.062) nM for control and 0.040 (0.027-0.061) nM for Alzheimer. Thus even though several previous studies have demonstrated marked atrophy of 5-HT containing neurites and 5-HT uptake sites in Alzheimer's disease, these findings are not found in the periphery on platelets. The platelet 5-HT uptake site cannot be used as a peripheral marker of Alzheimer's disease.
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
January 1993,
Psychopharmacology,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
August 1990,
Brain research,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
October 1994,
Biological psychiatry,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
January 1990,
Journal of neural transmission. Supplementum,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
September 2001,
Psychiatry research,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
September 1993,
Biological psychiatry,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
December 1989,
British journal of pharmacology,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
June 1994,
Psychopharmacology,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
November 1989,
European journal of pharmacology,
A Andersson, and
R Adolfsson, and
K Eriksson, and
J Marcusson
January 1987,
Journal of psychopharmacology (Oxford, England),
